Article Images
Content deleted Content added
Line 74: == Pharmacology == Ropinirole acts as a [[Dopamine receptor D2|D<sub>2</sub>]], [[Dopamine receptor D3|D<sub>3</sub>]], and [[Dopamine receptor D4|D<sub>4</sub>]] [[dopamine]] [[receptor (biochemistry)|receptor]] [[agonist]] with highest [[Chemical affinity|affinity]] for D<sub>3</sub>, which are mostly found in the limbic areas.<ref>{{Cite journal|last1=Shill|first1=Holly A.|last2=Stacy|first2=Mark|date=2009|title=Update on ropinirole in the treatment of Parkinson's disease Ropinirole is metabolized primarily by [[cytochrome P450]] [[CYP1A2]] to form two [[metabolites]]; SK&F-104557 and SK&F-89124, both of which are renally excreted,<ref name="RPL">[http://www.richmondpharmacology.com/downloads/Publications/L3%20MDS%20ESRD%20poster.pdf An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole] | Authors: Debra J. Tompson, Deborah Hewens, Nancy Earl, David Oliveira, Jorg Taubel, Suzanne Swan, Luigi Giorgi | 13th International Congress of Parkinson’s Disease and Movement Disorders, Paris, France, June 7–11, 2009</ref> and at doses higher than clinical, is also metabolized by [[CYP3A4]]. At doses greater than 24 mg, [[CYP2D6]] may be inhibited, although this has been tested only [[in vitro]].<ref name=TompsonD/> | |||